Skip to content
Back to CORT

Corcept Therapeutics Inc

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
109
Purchases
2
Sales
107
Purchase value
$3.31M
Sale value
$97.67M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Daniel N Swisher JRDirector
4Rule 10b5-1 plan disclosed
Filed Nov 13, 2026Period of report Nov 10, 20260001193125-26-460765
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 10, 2026
Common StockF11,500$74.07$111.11K0Direct
Filing footnotes · 3
  1. F1The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 3, 2026 in effect at the time of this transaction.
  2. F2Fully exercisable.
  3. F3The Reporting Person previously transferred 12,500 shares underlying the stock option to his ex-spouse. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
Open on SEC EDGAR
Maduck SeanSee Remarks
4Rule 10b5-1 plan disclosed
Filed Nov 4, 2026Period of report Nov 2, 20260001193125-26-447906
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 3, 2026
Common StockF2F4F18,617$82.0198$706.76K14,480Direct
SaleNov 3, 2026
Common StockF2F5F14,542$82.6756$375.51K9,938Direct
SaleNov 2, 2026
Common StockF2F3F111,841$81.4183$964.07K9,938Direct
Filing footnotes · 13
  1. F1Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F10Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  3. F11Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  4. F12Represents the shares held by SNM 2026-2 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  5. F13Fully exercisable.
  6. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
  7. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.12 to $82.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  8. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.25 to $82.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  9. F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.34 to $83.02 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  10. F6Reflects a transfer of shares of Common Stock between direct and indirect accounts over which the Reporting Person has beneficial ownership. The transfer resulted only in a change in the form of the Reporting Person's beneficial ownership and is exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934, as amended.
  11. F7Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
  12. F8Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
  13. F9Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
Open on SEC EDGAR
Roberto Wandenkolk VieiraPresident, Oncology
4Rule 10b5-1 plan disclosed
Filed Nov 4, 2026Period of report Nov 2, 20260001193125-26-447899
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 2, 2026
Common StockF2F3F16,657$80.7326$537.44K5,622Direct
SaleNov 2, 2026
Common StockF2F4F11,676$81.5226$136.63K3,946Direct
Filing footnotes · 5
  1. F1Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.15 to $81.12 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.17 to $82.07 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.
Open on SEC EDGAR
James N WilsonDirector
4Rule 10b5-1 plan disclosed
Filed Oct 16, 2026Period of report Oct 15, 20260001193125-26-424350
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 15, 2026
Common StockF1F2F56,654$114.4751$761.72K1,057,889IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleOct 15, 2026
Common StockF1F3F53,046$115.3895$351.48K1,054,843IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleOct 15, 2026
Common StockF1F4F5300$116.2967$34.89K1,054,543IndirectJames N. Wilson and Pamela D. Wilson Trust
Filing footnotes · 5
  1. F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.13 to $115.12 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.16 to $116.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.19 to $116.35 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Open on SEC EDGAR
Roberto Wandenkolk VieiraPresident, Oncology
4Rule 10b5-1 plan disclosed
Filed Oct 5, 2026Period of report Oct 2, 20260001193125-26-414688
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 2, 2026
Common StockF2F3F11,100$114.5205$125.97K11,179Direct
SaleOct 2, 2026
Common StockF2F4F12,086$115.7298$241.41K9,093Direct
SaleOct 2, 2026
Common StockF2F5F15,147$116.585$600.06K3,946Direct
Filing footnotes · 6
  1. F1Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.03 to $114.90 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.16 to $116.04 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.24 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  6. F6Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.
Open on SEC EDGAR
Joseph Douglas LyonSee Remarks
4Rule 10b5-1 plan disclosed
Filed Oct 5, 2026Period of report Oct 1, 20260001193125-26-414684
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 2, 2026
Common StockF2F4F14,446$115.697$514.39K10,427Direct
SaleOct 2, 2026
Common StockF2F5F14,744$116.5407$552.87K5,683Direct
SaleOct 1, 2026
Common StockF2F3F1810$115.3985$93.47K5,683Direct
Filing footnotes · 6
  1. F1Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $116.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.25 to $116.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  6. F6Fully exercisable.
Open on SEC EDGAR
Sean MaduckSee Remarks
4Rule 10b5-1 plan disclosed
Filed Oct 5, 2026Period of report Oct 1, 20260001193125-26-414674
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 2, 2026
Common StockF2F4F115,843$116.1233$1.84M18,682Direct
SaleOct 2, 2026
Common StockF2F5F18,744$116.5534$1.02M9,938Direct
SaleOct 1, 2026
Common StockF2F3F1413$115.5373$47.72K9,938Direct
Filing footnotes · 11
  1. F1Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F10Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  3. F11Fully exercisable.
  4. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
  5. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  6. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  7. F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  8. F6Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
  9. F7Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
  10. F8Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  11. F9Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
Open on SEC EDGAR
Roberto Wandenkolk VieiraPresident, Oncology
4Rule 10b5-1 plan disclosed
Filed Sep 18, 2026Period of report Sep 16, 20260001193125-26-395837
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 16, 2026
Common StockF1F2296$100.82$29.84K3,946Direct
Filing footnotes · 2
  1. F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
  2. F2Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Open on SEC EDGAR
James N WilsonDirector
4Rule 10b5-1 plan disclosed
Filed Sep 16, 2026Period of report Sep 15, 20260001193125-26-393124
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 15, 2026
Common StockF1F2F56,800$110.2698$749.83K1,067,743IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleSep 15, 2026
Common StockF1F3F5400$110.8363$44.33K1,067,343IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleSep 15, 2026
Common StockF1F4F52,800$111.7039$312.77K1,064,543IndirectJames N. Wilson and Pamela D. Wilson Trust
Filing footnotes · 5
  1. F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.66 to $110.64 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.665 to $111.095 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.70 to $111.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Open on SEC EDGAR
Joseph Douglas LyonSee Remarks
4Rule 10b5-1 plan disclosed
Filed Sep 16, 2026Period of report Sep 14, 20260001193125-26-393125
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 14, 2026
Common StockF2F3F17,812$113.3206$885.26K7,871Direct
SaleSep 14, 2026
Common StockF2F4F12,188$114.1163$249.69K5,683Direct
Filing footnotes · 5
  1. F1Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.81 to $113.72 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.92 to $114.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5Fully exercisable.
Open on SEC EDGAR
Roberto Wandenkolk VieiraPresident, Oncology
4Rule 10b5-1 plan disclosed
Filed Sep 3, 2026Period of report Sep 1, 20260001193125-26-382456
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 2, 2026
Common StockF8F9F723,600$109.3506$2.58M38,975Direct
SaleSep 2, 2026
Common StockF8F10F723,770$110.7004$2.63M15,205Direct
SaleSep 2, 2026
Common StockF8F11F71,537$111.3733$171.18K13,668Direct
SaleSep 2, 2026
Common StockF8F12F7974$112.3966$109.47K12,694Direct
SaleSep 2, 2026
Common StockF8F13F71,606$113.7187$182.63K11,088Direct
SaleSep 2, 2026
Common StockF8F14F75,621$114.5779$644.04K5,467Direct
SaleSep 2, 2026
Common StockF8F15F71,225$115.4395$141.41K4,242Direct
Filing footnotes · 16
  1. F1The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
  2. F10Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F11Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F12Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F13Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  6. F14Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  7. F15Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  8. F16Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.
  9. F2In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  10. F3Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  11. F4Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  12. F5These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
  13. F6The closing price on September 1, 2026 was used to calculate the withholding obligation.
  14. F7Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  15. F8This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
  16. F9Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Open on SEC EDGAR
Sean MaduckSee Remarks
4Rule 10b5-1 plan disclosed
Filed Sep 3, 2026Period of report Sep 1, 20260001193125-26-382474
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 1, 2026
Common StockF2F3F111,730$113.9351$1.34M23,025Direct
SaleSep 1, 2026
Common StockF2F4F110,989$114.7118$1.26M12,036Direct
SaleSep 1, 2026
Common StockF2F5F12,281$115.6118$263.71K9,755Direct
Filing footnotes · 17
  1. F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F10The closing price on September 1, 2026 was used to calculate the withholding obligation.
  3. F11Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  4. F12Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
  5. F13Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
  6. F14Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  7. F15Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  8. F16Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  9. F17Fully exercisable.
  10. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
  11. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.36 to $114.34 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  12. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.365 to $115.295 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  13. F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.37 to $115.82 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  14. F6The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
  15. F7In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  16. F8Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  17. F9These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
Open on SEC EDGAR
Kimberly ParkDirector
4
Filed Aug 28, 2026Period of report Aug 26, 20260001193125-26-374607
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 26, 2026
Common StockF226,685$122.5471$3.27M0Direct
Filing footnotes · 3
  1. F1These shares were withheld by the Issuer in order to cover the exercise price in connection with the net exercise of stock options reported herein.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $122.50 to $122.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3Fully exercisable.
Open on SEC EDGAR
Sean MaduckSee Remarks
4Rule 10b5-1 plan disclosed
Filed Aug 27, 2026Period of report Aug 25, 20260001193125-26-371388
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 25, 2026
Common StockF2F3F125,085$125.4676$3.15M15,625Direct
SaleAug 25, 2026
Common StockF2F4F15,870$126.0588$739.97K9,755Direct
Filing footnotes · 10
  1. F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F10Fully exercisable.
  3. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
  4. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $125.00 to $125.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $126.00 to $126.23 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  6. F5Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
  7. F6Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
  8. F7Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  9. F8Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  10. F9Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Open on SEC EDGAR
David L MahoneyDirector
4Rule 10b5-1 plan disclosed
Filed Aug 20, 2026Period of report Aug 18, 20260001193125-26-359255
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 18, 2026
Common StockF1F24,984$117.4716$585.48K1,232,161IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
SaleAug 18, 2026
Common StockF1F391,167$118.2376$10.78M1,140,994IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
SaleAug 18, 2026
Common StockF1F47,055$118.8817$838.71K1,133,939IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
SaleAug 18, 2026
Common StockF1F5400$119.6381$47.86K1,133,539IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
Filing footnotes · 5
  1. F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.595 to $117.59. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.60 to $118.595. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.60 to $119.345. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
  5. F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.605 to $119.6775. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Open on SEC EDGAR
Gary Charles RobbChief Business Officer
4
Filed Aug 18, 2026Period of report Aug 17, 20260001193125-26-355560
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 17, 2026
Common StockF2F310,000$116.2572$1.16M39,716IndirectGary Charles Robb TTE Robb Revocable Trust
Filing footnotes · 5
  1. F1Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.00 to $116.54 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
  3. F3These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.
  4. F4These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
  5. F5These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
Open on SEC EDGAR
Sean MaduckSee Remarks
4Rule 10b5-1 plan disclosed
Filed Aug 18, 2026Period of report Aug 14, 20260001193125-26-355563
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 14, 2026
Common StockF2F13,664$114.49$419.49K9,755Direct
Filing footnotes · 8
  1. F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
  3. F3Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
  4. F4Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
  5. F5Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  6. F6Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  7. F7Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  8. F8Fully exercisable.
Open on SEC EDGAR
James N WilsonDirector
4Rule 10b5-1 plan disclosed
Filed Aug 18, 2026Period of report Aug 14, 20260001193125-26-355562
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 14, 2026
Common StockF1F2F53,053$110.4949$337.34K1,081,490IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleAug 14, 2026
Common StockF1F3F54,668$111.4425$520.21K1,076,822IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleAug 14, 2026
Common StockF1F4F52,279$112.6398$256.71K1,074,543IndirectJames N. Wilson and Pamela D. Wilson Trust
Filing footnotes · 5
  1. F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.00 to $110.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.01 to $112.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.51 to $112.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Open on SEC EDGAR
Sean MaduckSee Remarks
4Rule 10b5-1 plan disclosed
Filed Aug 12, 2026Period of report Aug 10, 20260001193125-26-346951
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 10, 2026
Common StockF2F3F11,031$114.5182$118.07K9,755Direct
Filing footnotes · 9
  1. F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.50 to $114.58 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
  5. F5Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
  6. F6Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  7. F7Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  8. F8Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  9. F9Fully exercisable.
Open on SEC EDGAR
William GuyerChief Development Officer
4Rule 10b5-1 plan disclosed
Filed Aug 12, 2026Period of report Aug 10, 20260001193125-26-346942
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 10, 2026
Common StockF2F3F111,530$113.1772$1.30M8,755Direct
SaleAug 10, 2026
Common StockF2F4F14,770$114.0371$543.96K3,985Direct
Filing footnotes · 5
  1. F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.80 to $113.75 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.98 to $114.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5Fully exercisable.
Open on SEC EDGAR
William GuyerChief Development Officer
4Rule 10b5-1 plan disclosed
Filed Aug 6, 2026Period of report Aug 4, 20260001193125-26-338637
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 4, 2026
Common StockF2F3F13,700$113.1248$418.56K3,985Direct
Filing footnotes · 4
  1. F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.92 to $113.455 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Fully exercisable.
Open on SEC EDGAR
Sean MaduckSee Remarks
4Rule 10b5-1 plan disclosed
Filed Aug 5, 2026Period of report Aug 3, 20260001193125-26-335617
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 3, 2026
Common StockF2F3F120,305$114.7045$2.33M9,755Direct
Filing footnotes · 9
  1. F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.49 to $115.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
  5. F5Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
  6. F6Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  7. F7Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  8. F8Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  9. F9Fully exercisable.
Open on SEC EDGAR
Joseph Douglas LyonSee Remarks
4
Filed Aug 5, 2026Period of report Aug 3, 20260001193125-26-335605
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 3, 2026
Common StockF11,540$114.16$175.81K5,495Direct
Filing footnotes · 1
  1. F1Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Open on SEC EDGAR
Atabak MokariChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Aug 3, 2026Period of report Jul 30, 20260001193125-26-330668
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 30, 2026
Common StockF2F3F14,200$105.5352$443.25K91,930Direct
SaleJul 30, 2026
Common StockF2F4F18,956$106.9553$957.89K82,974Direct
SaleJul 30, 2026
Common StockF2F1400$108.46$43.38K82,574Direct
SaleJul 30, 2026
Common StockF2F5F12,202$110.0283$242.28K80,372Direct
SaleJul 30, 2026
Common StockF2F1600$110.95$66.57K79,772Direct
SaleJul 30, 2026
Common StockF2F6F14,700$113.1789$531.94K75,072Direct
SaleJul 30, 2026
Common StockF2F7F115,477$114.9601$1.78M59,595Direct
SaleJul 30, 2026
Common StockF2F8F114,222$115.8669$1.65M45,373Direct
SaleJul 30, 2026
Common StockF2F9F17,089$116.9561$829.10K38,284Direct
SaleJul 30, 2026
Common StockF2F10F18,267$117.9329$974.95K30,017Direct
SaleJul 30, 2026
Common StockF2F11F14,783$118.7346$567.91K25,234Direct
SaleJul 30, 2026
Common StockF2F12F18,103$119.9481$971.94K17,131Direct
SaleJul 30, 2026
Common StockF2F13F11,001$120.6749$120.80K16,130Direct
Filing footnotes · 14
  1. F1Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F10Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.41 to $118.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F11Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.42 to $119.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F12Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.42 to $120.41 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F13Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $120.49 to $120.84 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  6. F14Fully exercisable.
  7. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
  8. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $105.305 to $106.2 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  9. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $106.75 to $107.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  10. F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.71 to $110.42 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  11. F6Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.96 to $113.89 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  12. F7Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.305 to $115.30 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  13. F8Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.35 to $116.27 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  14. F9Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.35 to $117.3 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Open on SEC EDGAR
James N WilsonDirector
4Rule 10b5-1 plan disclosed
Filed Jul 17, 2026Period of report Jul 15, 20260001193125-26-308061
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 15, 2026
Common StockF1F2F61,079$86.7777$93.63K1,093,464IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleJul 15, 2026
Common StockF1F3F63,969$87.7356$348.22K1,089,495IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleJul 15, 2026
Common StockF1F4F62,974$88.8105$264.12K1,086,521IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleJul 15, 2026
Common StockF1F5F61,978$89.4881$177.01K1,084,543IndirectJames N. Wilson and Pamela D. Wilson Trust
Filing footnotes · 6
  1. F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.20 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.17 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.31 to $89.665 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  6. F6Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Open on SEC EDGAR
Atabak MokariChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Jul 17, 2026Period of report Jul 15, 20260001193125-26-308058
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 15, 2026
Common StockF2F3F17,919$86.776$687.18K48,211Direct
SaleJul 15, 2026
Common StockF2F4F128,460$87.8863$2.50M19,751Direct
SaleJul 15, 2026
Common StockF2F5F13,520$88.3016$310.82K16,231Direct
SaleJul 15, 2026
Common StockF2F6F1101$89.4282$9.03K16,130Direct
Filing footnotes · 7
  1. F1Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.19 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.07 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  6. F6Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.25 to $89.43 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  7. F7Fully exercisable.
Open on SEC EDGAR
William GuyerChief Development Officer
4Rule 10b5-1 plan disclosed
Filed Jul 8, 2026Period of report Jul 7, 20260001193125-26-298865
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 7, 2026
Common StockF2F3F119,048$93.1059$1.77M4,937Direct
SaleJul 7, 2026
Common StockF2F4F1952$93.5383$89.05K3,985Direct
Filing footnotes · 5
  1. F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $92.50 to $93.43 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $93.52 to $93.665 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5Fully exercisable.
Open on SEC EDGAR
Sean MaduckSee Remarks
4Rule 10b5-1 plan disclosed
Filed Jul 6, 2026Period of report Jul 1, 20260001193125-26-296296
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 1, 2026
Common StockF2F3F111,024$87.3349$962.78K23,731Direct
SaleJul 1, 2026
Common StockF2F4F12,801$88.5127$247.92K20,930Direct
SaleJul 1, 2026
Common StockF2F5F111,175$89.3094$998.03K9,755Direct
Filing footnotes · 11
  1. F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F10Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  3. F11Fully exercisable.
  4. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
  5. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.95 to $87.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  6. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.98 to $88.97 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  7. F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.09 to $89.37 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  8. F6Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
  9. F7Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
  10. F8Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  11. F9Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
Open on SEC EDGAR
David L MahoneyDirector
4
Filed Jun 18, 2026Period of report Jun 17, 20260001193125-26-275963
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 17, 2026
Common StockF120,000$84.5253$1.69M26,147IndirectThe Black Dog Private Foundation
Filing footnotes · 1
  1. F1Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.44 to $85.11. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Open on SEC EDGAR
James N WilsonDirector
4Rule 10b5-1 plan disclosed
Filed Jun 18, 2026Period of report Jun 16, 20260001193125-26-275964
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 16, 2026
Common StockF1F2F44,177$82.6948$345.42K1,100,366IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleJun 16, 2026
Common StockF1F3F45,823$83.5708$486.63K1,094,543IndirectJames N. Wilson and Pamela D. Wilson Trust
Filing footnotes · 4
  1. F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.13 to $83.125 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.16 to $83.935 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Open on SEC EDGAR
Atabak MokariChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Jun 17, 2026Period of report Jun 15, 20260001193125-26-274224
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 15, 2026
Common StockF2F3F19,434$80.0216$754.92K46,696Direct
SaleJun 15, 2026
Common StockF2F4F111,081$80.9424$896.92K35,615Direct
SaleJun 15, 2026
Common StockF2F5F119,483$81.8092$1.59M16,132Direct
SaleJun 15, 2026
Common StockF2F12$82.45$164.9016,130Direct
Filing footnotes · 6
  1. F1Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $80.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.40 to $81.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.40 to $82.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  6. F6Fully exercisable.
Open on SEC EDGAR
William GuyerChief Development Officer
4Rule 10b5-1 plan disclosed
Filed Jun 4, 2026Period of report Jun 2, 20260001193125-26-257618
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 2, 2026
Common StockF2F3F120,000$70.60$1.41M3,985Direct
Filing footnotes · 4
  1. F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.44 to $70.86 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Fully exercisable.
Open on SEC EDGAR
Sean MaduckSee Remarks
4Rule 10b5-1 plan disclosed
Filed Jun 3, 2026Period of report Jun 1, 20260001193125-26-256013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 1, 2026
Common StockF2F3F121,069$70.1068$1.48M12,908Direct
SaleJun 1, 2026
Common StockF2F4F13,931$70.7462$278.10K8,977Direct
Filing footnotes · 16
  1. F1Includes 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F10Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  3. F11Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
  4. F12Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
  5. F13Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  6. F14Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  7. F15Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  8. F16Fully exercisable.
  9. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
  10. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.49 to $70.48 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  11. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.49 to $70.95 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  12. F5The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026.
  13. F6In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  14. F7Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  15. F8These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
  16. F9The closing price on June 1, 2026 was used to calculate the withholding obligation.
Open on SEC EDGAR
Atabak MokariChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Jun 3, 2026Period of report Jun 1, 20260001193125-26-256011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 1, 2026
Common StockF2F3F140,000$70.0001$2.80M15,257Direct
Filing footnotes · 10
  1. F1Includes 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F10Fully exercisable.
  3. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
  4. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.00 to $70.01 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F4The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026.
  6. F5In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  7. F6Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  8. F7These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
  9. F8The closing price on June 1, 2026 was used to calculate the withholding obligation.
  10. F9Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Open on SEC EDGAR
Joseph K BelanoffDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Jun 2, 2026Period of report May 29, 20260001193125-26-253459
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 1, 2026
Common StockF6F112,837$69.74$895.25K2,565,489IndirectJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02
Filing footnotes · 6
  1. F1Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
  2. F2Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust.
  3. F3Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee.
  4. F4Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust.
  5. F5Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee.
  6. F6This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
Open on SEC EDGAR
Joseph Douglas LyonSee Remarks
4
Filed May 29, 2026Period of report May 27, 20260001193125-26-248977
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 27, 2026
Common StockF15,000$65.00$325.00K6,230Direct
Filing footnotes · 1
  1. F1Includes 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Open on SEC EDGAR
Sean MaduckSee Remarks
4Rule 10b5-1 plan disclosed
Filed May 29, 2026Period of report May 27, 20260001193125-26-248967
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 27, 2026
Common StockF2F3F154,575$65.3711$3.57M29,402Direct
SaleMay 27, 2026
Common StockF2F4F120,425$66.1599$1.35M8,977Direct
Filing footnotes · 10
  1. F1Includes 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F10Fully exercisable.
  3. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
  4. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $65.00 to $65.99 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $66.00 to $66.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  6. F5Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
  7. F6Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
  8. F7Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  9. F8Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  10. F9Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Open on SEC EDGAR
William GuyerChief Development Officer
4Rule 10b5-1 plan disclosed
Filed May 7, 2026Period of report May 5, 20260001193125-26-212118
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 5, 2026
Common StockF2F3F120,000$51.83$1.04M2,231Direct
Filing footnotes · 4
  1. F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $51.60 to $52.05 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Fully exercisable.
Open on SEC EDGAR
Joseph K BelanoffDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed May 5, 2026Period of report May 1, 20260001193125-26-206540
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 1, 2026
Common StockF1F2F340,000$50.0965$2.00M2,878,326IndirectJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02
Filing footnotes · 3
  1. F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.35 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Open on SEC EDGAR
William GuyerChief Development Officer
4Rule 10b5-1 plan disclosed
Filed Apr 8, 2026Period of report Apr 7, 20260001193125-26-148497
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 7, 2026
Common StockF2F3F120,000$40.97$819.40K2,231Direct
Filing footnotes · 4
  1. F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $40.85 to $41.30 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Fully exercisable.
Open on SEC EDGAR
Joseph K BelanoffDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Mar 27, 2026Period of report Mar 25, 20260001193125-26-129143
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 25, 2026
Common StockF1F2F326,198$50.0735$1.31M2,918,326IndirectJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02
Filing footnotes · 3
  1. F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.32 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Open on SEC EDGAR
William GuyerChief Development Officer
4Rule 10b5-1 plan disclosed
Filed Mar 24, 2026Period of report Mar 20, 20260001193125-26-122136
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 20, 2026
Common StockF2F3F111,767$36.01$423.73K2,231Direct
Filing footnotes · 4
  1. F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Fully exercisable.
Open on SEC EDGAR
G Leonard Baker JRDirector
4
Filed Mar 19, 2026Period of report Mar 17, 20260001201715-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 17, 2026
Common StockF175,782$33.0022$2.50M1,122,413Direct
PurchaseMar 17, 2026
Common StockF224,218$33.5633$812.84K1,146,631Direct
Filing footnotes · 4
  1. F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.43 to $33.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.44 to $33.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  3. F3Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
  4. F4Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.
Open on SEC EDGAR
William GuyerChief Development Officer
4Rule 10b5-1 plan disclosed
Filed Mar 6, 2026Period of report Mar 4, 20260001193125-26-096653
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 4, 2026
Common StockF2F3F18,233$35.9949$296.35K2,231Direct
Filing footnotes · 4
  1. F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.05 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4Fully exercisable.
Open on SEC EDGAR
William GuyerChief Development Officer
4Rule 10b5-1 plan disclosed
Filed Feb 5, 2026Period of report Feb 3, 20260001193125-26-039717
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 3, 2026
Common StockF1F220,000$40.8667$817.33K1,235Direct
Filing footnotes · 3
  1. F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $40.71 to $41.2804 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3Fully exercisable.
Open on SEC EDGAR
William GuyerChief Development Officer
4Rule 10b5-1 plan disclosed
Filed Jan 8, 2026Period of report Jan 6, 20260001193125-26-008023
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 6, 2026
Common StockF1F220,000$35.1828$703.66K1,235Direct
Filing footnotes · 3
  1. F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $34.96 to $35.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3Fully exercisable.
Open on SEC EDGAR
William GuyerChief Development Officer
4Rule 10b5-1 plan disclosed
Filed Dec 3, 2025Period of report Dec 1, 20250001193125-25-307282
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 2, 2025
Common StockF6F719,360$80.0499$1.55M1,875Direct
SaleDec 2, 2025
Common StockF6640$80.875$51.76K1,235Direct
Filing footnotes · 8
  1. F1The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025.
  2. F2In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  3. F3Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  4. F4Represents the shares held by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee.
  5. F5Transfer of shares without consideration to the Reporting Person.
  6. F6This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
  7. F7Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.78 to $80.68 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  8. F8Fully exercisable.
Open on SEC EDGAR
Sean MaduckSee Remarks
4Rule 10b5-1 plan disclosed
Filed Dec 3, 2025Period of report Dec 1, 20250001193125-25-307251
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 1, 2025
Common StockF2F3F120,000$79.5245$1.59M7,904Direct
Filing footnotes · 12
  1. F1Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F10Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
  3. F11Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  4. F12Fully exercisable.
  5. F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.
  6. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $79.81 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  7. F4The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025.
  8. F5In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  9. F6Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  10. F7These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
  11. F8The closing price on December 1, 2025 was used to calculate the withholding obligation.
  12. F9Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
Open on SEC EDGAR
Joseph Douglas LyonSee Remarks
4Rule 10b5-1 plan disclosed
Filed Dec 3, 2025Period of report Dec 1, 20250001193125-25-307229
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 1, 2025
Common StockF2F3F15,000$79.5263$397.63K10,277Direct
Filing footnotes · 9
  1. F1Includes 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
  3. F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $79.73 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025.
  5. F5In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  6. F6Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  7. F7These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
  8. F8The closing price on December 1, 2025 was used to calculate the withholding obligation.
  9. F9Fully exercisable.
Open on SEC EDGAR
Joseph K BelanoffDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Dec 3, 2025Period of report Dec 1, 20250001193125-25-307204
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 1, 2025
Common StockF1F2F340,000$79.7699$3.19M2,701,370IndirectJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02
Filing footnotes · 3
  1. F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
  2. F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.65 to $79.97 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.